AMRI’s discovery biology team accelerates your program toward the clinic and commercialization with our best-in-class, customized solutions. Our experts provide integration with medicinal chemistry, DMPK and analytical capabilities as well as seamless transition for your project throughout the drug discovery and development continuum. From concept to candidate, our scientific expertise and advanced technology platforms enable you to reduce costs, shorten time cycles and achieve better outcomes.
Our complete suite of discovery biology capabilities includes:
- Protein expression, purification and conjugation
- Cell line development and CRISPR gene editing applications
- Assay development and validation
- High-throughput screening (HTS)
- High-content screening
- Target identification and validation
- Screening by mass spectrometry
- Label-free screening
- In vitro pharmacology/DMPK
- Structural biology — crystallization trials and crystallography
- Bioanalysis, pharmacokinetics (PK)
- Physicochemical properties and permeability
- Metabolic stability and metabolite identification, reactive metabolite screening
- CYP phenotyping, inhibition and induction
- Antibody drug conjugate optimization (warhead, linker and conjugation condition)
- Therapeutic protein analysis: High-resolution mass spectrometry, UHPLC, size-exclusion chromatography/multiangle light scattering/refractive index SEC MALS RI and limulus amebocyte lysate (LAL) assay